Tisbury Pharmaceuticals

About

Funding history · 1 round · $32.0M total

Q&A

What is Tisbury Pharmaceuticals' primary focus?

Tisbury Pharmaceuticals is a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of treatments for primary open-angle glaucoma.

What is the status of Tisbury Pharmaceuticals?

Tisbury Pharmaceuticals is currently inactive, having ceased to operate in November 2019.

When was Tisbury Pharmaceuticals founded?

Tisbury Pharmaceuticals was founded in January 2017.

What is the name of Tisbury Pharmaceuticals' clinical candidate?

Tisbury Pharmaceuticals' clinical candidate is R-801, which accelerates flow through the trabecular meshwork via redox catalysis and K+-ATP channel activation.

How much funding has Tisbury Pharmaceuticals raised in total?

Tisbury Pharmaceuticals has raised a total of $32,000,000 USD.

Which investors participated in Tisbury Pharmaceuticals' funding round?

In June 2017, OrbiMed and Clarus Ventures participated in Tisbury Pharmaceuticals' funding round.

What is the employee count for Tisbury Pharmaceuticals?

Tisbury Pharmaceuticals has 1-10 employees.

What is Tisbury Pharmaceuticals' primary sector?

Tisbury Pharmaceuticals' primary sector is Health Tech & Life Sciences.

Team · 1

Andrew Salzman

Founder · Founder

LinkedIn ↗

Sectors & technology

Tags